Have a feature idea you'd love to see implemented?
Let us know!
SNDX Syndax Pharmaceuticals Inc
Price (delayed)
$12.805
Market cap
$1.09B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.64
Enterprise value
$960.62M
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin-MLL binding interaction, axatilimab,
Highlights
SNDX's debt has plunged by 54% YoY and by 24% from the previous quarter
SNDX's equity is down by 16% QoQ but it is up by 2% YoY
The net income has plunged by 69% YoY and by 12% from the previous quarter
The EPS has declined by 41% year-on-year and by 7% since the previous quarter
Key stats
What are the main financial stats of SNDX
Market
Valuations
Earnings
Shares outstanding
85.36M
Market cap
$1.09B
Enterprise value
$960.62M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.97
Price to sales (P/S)
68.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
60.04
Revenue
$16M
Gross profit
$16M
Net income
-$297.06M
EBIT
-$296.88M
EBITDA
-$295.84M
Free cash flow
-$258.86M
Per share
Balance sheet
Liquidity
EPS
-$3.64
EPS diluted
-$3.64
Free cash flow per share
-$3.03
Book value per share
$4.31
Revenue per share
$0.19
TBVPS
$4.98
Total assets
$425.81M
Total liabilities
$59.38M
Debt
$854,000
Equity
$366.43M
Working capital
$355.43M
Debt to equity
0
Current ratio
6.99
Quick ratio
6.91
Net debt/EBITDA
0.45
Margins
Efficiency
Dividend
EBITDA margin
-1,849%
Gross margin
100%
Net margin
-1,856.6%
Operating margin
-2,007.6%
Return on assets
-57.7%
Return on equity
-64.3%
Return on invested capital
-98.7%
Return on capital employed
-81%
Return on sales
-1,855.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SNDX stock price
How has the Syndax Pharmaceuticals stock price performed over time
Intraday
1.63%
1 week
-7.28%
1 month
-8.08%
1 year
-42.42%
YTD
-3.14%
QTD
-3.14%
Financial performance
How have Syndax Pharmaceuticals's revenue and profit performed over time
Revenue
$16M
Gross profit
$16M
Operating income
-$321.21M
Net income
-$297.06M
Gross margin
100%
Net margin
-1,856.6%
The operating margin has surged by 76% since the previous quarter
SNDX's net margin has soared by 75% from the previous quarter
The net income has plunged by 69% YoY and by 12% from the previous quarter
The operating income has plunged by 66% YoY and by 12% from the previous quarter
Growth
What is Syndax Pharmaceuticals's growth rate over time
Valuation
What is Syndax Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.97
P/S
68.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
60.04
The EPS has declined by 41% year-on-year and by 7% since the previous quarter
SNDX's price to book (P/B) is 23% lower than its 5-year quarterly average of 3.8 and 23% lower than its last 4 quarters average of 3.8
SNDX's equity is down by 16% QoQ but it is up by 2% YoY
Efficiency
How efficient is Syndax Pharmaceuticals business performance
The return on invested capital has dropped by 89% year-on-year and by 16% since the previous quarter
The return on sales has surged by 75% since the previous quarter
The company's return on equity has shrunk by 52% YoY and by 12% QoQ
Syndax Pharmaceuticals's return on assets has decreased by 46% YoY and by 11% QoQ
Dividends
What is SNDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SNDX.
Financial health
How did Syndax Pharmaceuticals financials performed over time
The total liabilities has increased by 48% year-on-year and by 39% since the previous quarter
The quick ratio has contracted by 34% from the previous quarter and by 28% YoY
SNDX's debt is 100% less than its equity
The debt to equity has dropped by 100% year-on-year
SNDX's debt has plunged by 54% YoY and by 24% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.